In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Eli Lilly's new insulin data —Sanofi x Regeneron autoimmune drugs —Gilead's new AI partnership Get the full rundown here: ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...

Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill ...

As a health journalist, I’m doing my best to keep up with all things weight loss drugs, but with headlines rolling in every ...

She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market.

The obesity pill could prove stiff competition for Eli Lilly and a sign to investors that Novo Nordisk might have a pipeline of next-generation drugs. Apply to the Most Innovative Companies Awards ...